DNA amplification-restricted transcriptiontranslation (DARTT), is based on DNA amplification by the polymerase chain reaction (PCR) and uses PCR to truncate protein-encoding DNA while adding transcriptional and translational initiation signals to the segment. The amplified DNA segments are transcribed into RNA and translated into protein in vitro and the synthesized proteins are used to define functional sites. DARTT was applied to rhesus rotavirus gene segment 4 cDNA in order to create a series ofcarboxyl-terminal truncations and new amino termini in the encoded VP4 capsid protein.
ciated with viral virulence (6, 7) and cell penetration (8) . VP4 is responsible for binding the erythrocyte protein glycophorin (9) and is the viral hemagglutinin (10) . Antibodies directed at VP4 inhibit viral hemagglutination, neutralize the virus in vitro (11) , and passively protect mice against rotavirus challenge in vivo (12) . VP4 also effectively induces protective immunity in animals and is immunogenic in young children (13) (14) (15) (16) .
In previous studies of monoclonal antibody (mAb) "escape" mutants, we have identified point mutations in VP4 that appeared to be involved in viral neutralization (4, 17) . However, this analysis did not determine whether neutralizing antibodies actually bound to these regions or whether the identified mutations elicited conformational changes at a distant site. In order to directly define the minimal VP4 polypeptides that are bound by selected neutralizing antibodies, a broadly applicable method for synthesizing a series oftruncated polypeptides has been devised. The procedure is called DNA amplification-restricted transcription-translation (DARTT) and is based on the polymerase chain reaction (PCR) (18) (19) (20) . We have applied DARTT analysis to the coding region of gene segment 4 of RRV and determined the minimal VP4 polypeptide required for neutralizing mAb recognition.
METHODS
Amplification, Transcription, and Translation. PCR, RNA transcription, and in vitro translation reactions were performed as described (16-18, 21, 22) . Briefly, the PCR reaction scheme was as follows: denaturation at 940C, 1 min; annealing at 42 or 50'C, depending on primer specificity, 2 min; DNA polymerization at 720C by Thermus aquaticus (Taq) DNA polymerase, 3 min. The reaction was repeated for 30 cycles with the DNA polymerization time being extended 10 sec with each successive cycle. To complete DNA strands and remove primers competitive for RNA polymerase binding, T4 DNA polymerase was added at the conclusion of each reaction for 30 plasmid, or an oligonucleotide contains a T3, T7, or SP6 DNA-dependent RNA polymerase initiation site adjacent to a cloned DNA's translation initiation codon, ATG (Fig. 1A) . PCR amplification with a vector-derived primer and an opposing cDNA insert-derived primer results in the synthesis of a truncated DNA that can subsequently be transcribed and translated. Applying this strategy to a number of negativesense insert primers results in the synthesis of discrete polypeptides containing a native amino terminus and a series of new carboxyl termini (Fig. LA) .
A complementary second method for truncating the polypeptides entails adding internal transcriptional and translational start signals to the DNA segment (Fig. 1B) . This is accomplished by synthesizing a 5'-end primer that contains the T3 RNA polymerase transcriptional start signal and adds a new ATG initiation codon in-frame to the protein coding regions of the DNA (Fig. 1B) . Amplifying between this T3-ATG primer and a negative-sense downstream primer (18, 19) results in 5'-end-restricted fragments that can be transcribed into RNA and translated into protein. Since the latter procedure truncates the protein product from the amino terminus and the former technique produces truncations from the carboxyl terminus, virtually any polypeptide can be synthesized by combining the two PCR protocols. tion (16) (17) (18) (19) . Amplified DNAs representing 1/20th ofthe total were electrophoresed in a 1% agarose gel and stained with ethidium bromide to assay the PCR reaction (Fig. 2) . Each amplification-restricted DNA contains transcriptional and translational initiation signals that were used in subsequent DARTT steps.
Prior to utilizing DARTT, deletions can be made without PCR by using unique restriction sites in the coding sequence that create 3'-end truncations. Run-off RNA transcripts can then be synthesized directly from plasmid-derived RNA polymerase signals and these transcripts can be translated in vitro.
Fig . 3A illustrates the total translation products derived by DARTT from the same series of amplified DNAs that appear in Fig. 2 . Each translated polypeptide was immunoprecipitated by hyperimmune anti-RRV guinea pig serum and screened for the presence of full-length translation products (Fig. 3B) . All of the DARTT-synthesized peptides were recognized by the hyperimmune serum, except for the shortest peptide (amino acids 1-60). Incomplete translation products seen in Figs. 3 and 4 presumably resulted from premature transcriptional or translational termination, or from RNA or protein degradation, and migrated faster than the full-length VP4 or the VP4 truncations.
The series of nested polypeptides were also studied by immunoprecipitation using a series of 11 previously characterized neutralizing mAbs (Table 1 ). An example of this form of analysis is seen in Fig. 4 . mAbs M2, M7, and 2G4 were previously shown by serologic and variant competition studies to be directed at a single neutralization domain on VP4 (23) . This epitope was classified as a crossreactive or heterotypic neutralization domain, since each of these mAbs neutralizes a group of serotypically diverse rotaviruses. Sequence analysis of neutralization-escape mutants produced with the M2, M7, and 2G4 mAbs localized the heterotypic neutralization epitope to the region of amino acid 392 in VP5 (4). We attempted to locate the functional peptide comprising the heterotypic neutralizing epitope on VP4 by determining the minimal essential polypeptide that could be immunoprecipitated by the neutralizing mAbs M2, M7, and 2G4. Immunoprecipitation revealed that M2, M7, and 2G4 reacted with the full-length VP4 protein and with truncated polypeptides including VP4 amino acids 1-474 but not with VP4-(1-450), a peptide extending from amino acid 1 to 450 (Table 1 ). Further analysis demonstrated that VP4-(247-474) was efficiently precipitated (Fig. 4, lanes 6-8) but that VP4-(247-450) (lanes 1-3) and VP4-(282-474) did not react with the mAbs (Table 1) . Hence it appears that these heterotypic, VP4-specific mAbs all require a minimum polypeptide of -228 amino acids (amino acids 247-474) of VP5 for binding and that deletions at either terminus abolish recognition by these neutralizing mAbs. Table 1 summarizes the results of immunoprecipitation studies using a series of DARTT-generated proteins to localize the remaining neutralizing mAb-binding domains of VP4. In addition to the heterotypic neutralizing mAbs, we analyzed the binding domain of eight largely serotype-specific neutralizing mAbs (M11, Al, A15, 1A9, 5D9, M14, 5C4, and 7A12). Table 1 lists the VP4 fragments that were precipitated by these VP8-specific mAbs as well as the fragments that were not recognized. The minimal essential binding domain for all of the VP8-specific neutralizing mAbs consists of amino acids 55-222 of VP4.
As might have been expected from mAb variant analysis, the eight mAbs that selected mutations in the VP8 region of VP4 immunoprecipitated polypeptides derived from VP8 but not ones derived from VP5 ( Table 1 ). The three mAbs that selected mutations in VP5 immunoprecipitated only peptides that were derived from VP5. These findings are consistent with previous observations that the binding of these VP4 mAbs is unaffected by proteolytic cleavage of VP4 (23) . Current findings further establish that the amino acids comprising the trypsin cleavage site (amino acids 231-246) are not present in the minimum peptide required for binding.
Although our studies have characterized minimal essential peptides required for binding of neutralizing mAbs, these findings must be taken as provisional. Since the selection of the primers used in the PCR was arbitrary and since we did not exhaustively generate nested polypeptides, some amino acids at the boundaries of the listed minimum peptides may not be required for mAb binding (Table 1) .
DISCUSSION
Various strategies have been used to localize the binding site of neutralizing mAbs. Sequence analyses of mAb-selected escape mutants have proven to be a powerful tool in these studies (4, 17, (24) (25) (26) (27) (lanes 1 and 6), M7 (lanes 2 and 7) , and 2G4 (lanes 3 and 8) , or hyperimmune anti-RRV serum (lanes 4 and 9) , or VP7-specific mAb 60 (lanes 5 and 10). The polypeptides precipitated represent amino acids 247-450 (lanes 1-5) or amino acids 247-474 (lanes 6-10) of the VP4 protein.
suggested that the amino acids defined by selected mutations (amino acids 88-188) could actually be present at conformationally adjacent positions of the VP8 polypeptide. Our observations suggest that synthetic peptides or short polypeptides of VP4 do not contain these neutralization epitopes and, therefore, may not be effective in stimulating neutralizing antibody. Conversely, expression of the full-length VP4 (9), the VP5 polypeptide 247-474, or the VP8 polypeptide 55-222 has been demonstrated to maintain these epitopes and the immunogenicity of these peptides should be investigated. It is likely that DARTT technology can also be used to investigate structure-function relationships for additional VP4 roles (hemagglutination and glycophorin binding, viral activation, and potential functions in fusion and cell attachment).
The major limitations of DARTT are the rather small quantities of protein produced by in vitro translation and the absence of posttranslational protein modifications. In addition, the truncated peptides studied here could potentially mask some epitopes through context-dependent secondary and tertiary protein conformations. However, we detected no evidence of masked binding sites, since more substantial polypeptide truncations from either end of VP4 failed to reveal additional reactive peptides ( 
